| 戴颖楠 李学奇 李馨 万晓京 韩颖.磺达肝癸钠应用于冠心病合并肾功能不全患者的临床研究[J].,2014,14(30):5970-5972 |
| 磺达肝癸钠应用于冠心病合并肾功能不全患者的临床研究 |
| Fondaparinux in the Treatment of Coronary Heart Disease Patientswith Renal Failure |
| |
| DOI： |
| 中文关键词: 磺达肝癸钠 肾功能不全 冠心病 |
| 英文关键词: Fondaparinux Renal failure Coronary heart disease |
| 基金项目:黑龙江省卫生厅科研课题（2010-138） |
|
| 摘要点击次数: 639 |
| 全文下载次数: 759 |
| 中文摘要: |
| 目的：观察磺达肝癸钠应用于冠心病急性冠脉综合征合并肾功能不全患者抗凝治疗的疗效及安全性。方法：216 例急性冠脉
综合征患者分为肾功能正常组及肾功能不全组，皮下注射磺达肝癸钠2.5 毫克，一日一次，连用8 天，比较两组治疗9 天内主要不
良心脏事件（MACE）及出血并发症的发生率和30 天及180 天的随访情况。结果：治疗9 天内及随访30 天、180 天期间，两组患者
主要不良心脏事件发生率无统计学差异（P＞0.05），治疗及随访期间两组均未出现严重出血及中度出血，肾功能不全组轻微出血
8 例，肾功能正常组轻微出血5 例，两组间比较差异无统计学意义（P＞0.05）。结论：磺达肝癸钠对于冠心病合并肾功能不全患者
的抗凝治疗是一种安全有效的药物。 |
| 英文摘要: |
| Objective:To observe the efficacy and safety of fondaparinux in the treatment of coronary heart disease patients with
renal failure.Methods:Two hundred and sixteen acute coronary syndrome patients were divided into two groups according to renal failure
group and normal renal function group. All the patients were given fondaparinux 2.5 mg per day subcutaneously for 8 days. Main adverse
cardiovascular events (MACE) and bleeding were compared between the two groups during the treatment and followed up for 30
and 180 days.Results:There were no significant differences in incidence of main adverse cardiovascular events between the two groups
(P>0.05). No major bleeding happened during the experiment. Minor bleeding occurred, 8 cases in the renal failure group and 5 cases in
the normal renal function group. There were no significant differences in incidence of bleeding between the two groups (P>0.05).Conclusion:Fondaparinux is an effective and safe drug in the treatment of coronary heart disease with renal failure. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
